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 59 
Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterial pathogen for which  60 
a vaccine is not available1,2. Employing the advantages of high-throughput DNA 61 
sequencing technology to vaccine design, we have analysed 2,083 GAS genomes from 62 
isolates causing significant morbidity and mortality in both developing and high-income 63 
countries. The global GAS population structure reveals extensive genomic heterogeneity 64 
overlaid with high levels of accessory gene plasticity. We identified the existence of more 65 
than 290 clinically associated genomic phylogroups across 22 countries, highlighting 66 
challenges in designing vaccines of global utility. We report the extent of natural genetic 67 
diversity across 150 GAS molecular emm types3, 484 multi-locus sequence types4 and 39 68 
M-protein clusters5. To determine vaccine candidate coverage, we investigated all 69 
previously described GAS antigens2,6 for gene carriage and gene sequence heterogeneity. 70 
Only 15 of 28 vaccine antigen candidates were found to have both low naturally occurring 71 
sequence variation and high (>99%) coverage across this diverse GAS population. 72 
Mapping global antigenic heterogeneity onto antigen protein structure provides a new 73 
approach for the identification of conserved epitopes on the surface of vaccine antigens. 74 
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This technological platform for vaccine coverage determination is equally applicable to 75 
prospective GAS antigens identified in future studies.  76 
 77 
GAS causes >700 million cases per year of superficial diseases such as pharyngitis and 78 
impetigo, and >600,000 cases per year of serious invasive infection. Immune sequelae such as 79 
acute rheumatic fever (ARF) and acute post-streptococcal glomerulonephritis each account for 80 
>400,000 cases per year1,2. As a consequence of ARF, >30 million people live with rheumatic 81 
heart disease, involving mitral and/or aortic regurgitation7. GAS ranks within the top 10 82 
infectious disease causes of human mortality worldwide1. Despite over 100 years of research, 83 
a commercial vaccine has not been developed2. Obstacles that have hindered development of 84 
a GAS vaccine include serotype diversity, GAS antigen carriage and variation, and vaccine 85 
safety concerns due to the immune sequelae caused by repeated GAS infection2,6. In 1978 the 86 
US Food and Drug Administration imposed a moratorium on human GAS vaccine trials due to 87 
concerns surrounding the potential of vaccine antigens to trigger autoimmunity. The US 88 
National Institute of Allergy and Infectious Diseases convened an expert workshop in 2004, 89 
which led to the lifting of the ban, but noted the possible involvement of M protein and group 90 
A carbohydrate antigens in autoimmunity8. A limited number of phase 1 clinical trials have 91 
since been conducted, focused primarily on multivalent N-terminal M protein vaccine 92 
candidates9,10. Other candidate GAS vaccine antigens that have demonstrated efficacy in 93 
animal models include the J8 peptide incorporated in the C-terminal repeats of M protein11, 94 
and non-M protein candidate vaccine antigens. The group A carbohydrate12,13 and multiple 95 
other surface or secreted proteins have been examined in preclinical vaccine studies 96 
(Supplementary Table 1)2,6. While a number of GAS antigens have been selected to avoid 97 
autoimmune concerns14,15 or specifically engineered to remove potential autoimmune-involved 98 
epitopes11,13, the capacity to investigate issues of serotype diversity, antigen carriage and 99 
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antigenic variation is impeded by the tremendous genetic diversity within the global GAS 100 
population16. To address this issue, we have developed a compendium of all GAS vaccine 101 
antigen sequences from 2,083 isolates employing high-throughput genomic technology. 102 
  103 
6 
 
RESULTS 104 
  105 
GAS population genetics 106 
We have compiled the most geographically and clinically diverse database of GAS genome 107 
sequences to date, comprising 2,083 strains, of which 645 isolates are reported for the first time 108 
(Supplementary Table 2). Our sampling strategy targeted geographical regions where GAS 109 
infection is endemic and encompassed isolates from both asymptomatic carriage and various 110 
clinical disease states. We included population-based studies from published databases and a 111 
limited number of representative isolates from emm-type specific microevolution studies, to 112 
prevent substantial epidemiological bias in data interpretation. Extracting the classical GAS 113 
epidemiological and genotypic markers of differentiation from 2,083 genome assemblies, the 114 
database constitutes 150 emm types (347 emm sub-types), 39 known M-protein clusters and 115 
484 multi-locus sequence types (MLSTs).  116 
 117 
To assess the genome-wide relationships within this global database, we identified the core 118 
genome of GAS to be 1,306 coding DNA sequences (CDS), based on an 80% nucleotide 119 
sequence coverage threshold and presence in >99% of the 2,083 genomes. To examine 120 
signatures of recombination within the core 1,306 genes, we analysed each core gene separately 121 
for evidence of mosaicism using the homologous recombination detection tool fastGEAR17. 122 
Using this algorithm, we estimated 890 core genes as having a recombinatorial evolutionary 123 
history (Supplementary Fig. 1, Supplementary Table 3), leaving 416 non-recombinogenic core 124 
genes (Supplementary Table 4) encoded by 266,960 bp of sequence  (~15% of a complete GAS 125 
genome). This is likely to be an under-representation of the total levels of GAS core genome 126 
recombination based on the limitations in sampling (for example, the potential of a donor 127 
genome not being represented in the collection) and/or the limitation that larger blocks of 128 
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recombination encompassing multiple genes may be missed. A pseudo-core sequence 129 
alignment was generated using these 416 core GAS genes. After removal of repeat sequences 130 
that can confound read mapping, a total of 30,738 single nucleotide polymorphisms (SNPs) 131 
and 23,923 parsimony informative sites were identified within the 266,960 bp pseudo-132 
reference. Phylogenetic analysis of the 416 gene pseudo-core GAS genome identified a deep 133 
branching star-like population structure indicative of an early radiation of GAS into distinct 134 
lineages (Fig. 1a). While the overall branching topology of the tree is supported by comparing 135 
genome-specific and lineage-specific SNPs (Supplementary Fig. 2), low bootstrap support 136 
towards the polytomous root of the tree prevents accurate inferences regarding the evolutionary 137 
relationships of the lineage-specific radiations (Fig 1a). Comparative analyses of the core 138 
phylogenetic tree topologies prior (1,306 genes) and post (416 genes) removal of the predicted 139 
recombinogenic CDS, did not affect the overall clustering of the isolates at the terminal 140 
branches of the tree (Supplementary Fig. 3), indicating that recombination events within the 141 
‘core’ GAS genome have blurred the ancestral evolutionary relationships between GAS 142 
lineages, yet have not introduced sufficient homoplasy to disrupt recent evolutionary signals.  143 
 144 
Applying the population network approach of PopPUNK18, we identified 299 distinct genetic 145 
clusters of evolutionarily related lineages, herein termed phylogroups (Figure 1a, 146 
Supplementary Fig. 4, 5a). This clustering approach is derived from core and accessory genetic 147 
distances between all 2,083 genomes using optimisation of a clustering network score to find 148 
a global distance boundary to define phylogroups (Supplementary Fig. 4a, b), and is designed 149 
to be iterative, meaning that new genomes can be added to this database using the same 150 
parameters and nomenclature as presented in this study without needing to refit the model. The 151 
median nucleotide divergence between phylogroups was 0.47% (range 0.25 – 0.56%), whereas 152 
genomes within the same phylogroup differed by a median divergence of 0.01% (range 0 – 153 
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0.14%). Of the 299 phylogroups, 206 phylogroups were represented by 2 or more isolates 154 
(Supplementary Fig. 4c, Supplementary Fig 5a). Overlaying the geographical origin of the 155 
isolates suggests that over half these 206 phylogroups have a diverse geographical distribution 156 
(Fig. 1a). The maintenance of so many distinct genetic lineages of GAS not appearing to be 157 
restricted by geographical boundaries is suggestive of rapid international spread followed by 158 
diversifying selection likely driven through immune selection and/or strain competition 159 
between phylogroups. Furthermore, these lineages do not appear to be restricted by clinical 160 
association. For example, 172 of the 206 phylogroups (83%) contain a clinically defined 161 
invasive GAS isolate (Supplementary Fig. 5b). The imbalanced nature of geographical and 162 
clinical sampling in this study prevents formal statistical inferences, and such phylogroup 163 
informed associations would require representative genomic epidemiological surveillance of 164 
the underlying population of GAS worldwide, which to date, does not exist. Examination of 165 
the distribution of the classic GAS molecular epidemiological markers relative to the 206 166 
multi-isolate phylogroups, revealed that 179 (87%) carried a single emm sequence type, 140 167 
(68%) carried a single emm sub-type and 129 (63%) were of a single multi-locus sequence type 168 
(Supplementary Fig. 6).  Only 3 (1.5%) of the emm sequence types and 55 (27%) of the emm 169 
sub-types were unique to a single phylogroup of 2 or more isolates, inferring extensive 170 
heterogeneity within GAS emm types. To further investigate these associations, we plotted the 171 
pairwise genetic distance of isolates based on common GAS epidemiological markers (emm 172 
type, emm sub-type, and MLST). Greater than 66% of emm types (84/128 multi-isolate 173 
representatives) and 32% of the emm sub-types (65/204 multi-isolate representatives) exceeded 174 
the minimal median nucleotide divergence between any two phylogroups (0.25% which 175 
equates to 655 SNPs within 416 core genes), showing that many emm types, emm sub-types 176 
and M-clusters do not share a close evolutionary history and in many cases represent different 177 
genetic lineages (Supplementary Fig. 7). Conversely, <1% of MLST (2/269 multi-isolate 178 
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representatives) exceeded the minimal median nucleotide divergence between phylogroups, 179 
yet MLST was a defining marker in only 27% of phylogroups. Furthermore, 6 of the 7 MLST 180 
genes (murI, xpt, gtr, gki, recP, and mutS) were identified to have evidence of homologous 181 
recombination within their evolutionary history while another MLST gene (yqiL) is not part of 182 
the core GAS genome (Supplementary Tables 3 and 4). Additionally, 3 emm18 genomes were 183 
also identified to have a deleted xpt gene19, and have been assigned the null allele xpt0 by 184 
MLST database curators.  Collectively, these data suggest that emm-type and MLST may have 185 
limited capacity for assigning evolutionary relationships within a globally evolving GAS 186 
population.  187 
 188 
The identification of hundreds of distinct genetic lineages (299 phylogroups) represents a 189 
challenge to unravelling the microevolution of dynamically evolving pathogenic bacterial 190 
populations. Indeed, only 32 of the phylogroups identified in this study contain a complete 191 
GAS reference genome (n = 68). Furthermore, the vast majority of publicly available GAS 192 
reference genomes are of strains and emm-types from North America and Europe, with very 193 
few reference types from high-disease burden geographical regions. Moreover, the emm-types 194 
circulating in these high-burden settings are often rarely encountered within high-income 195 
regions.  To enable future research into global and regional GAS population and evolutionary 196 
dynamics, 30 isolates representing geographically and genetically distinct samples were 197 
completely sequenced using the long-read PacBio platform.  The average size of these new 198 
reference genomes was 1,810,671 bp (ranging from 1,701,466 bp to 1,950,606) with 5 strains 199 
containing circular plasmids ranging from 2,645 bp to 6,485 bp in size (Supplementary Table 200 
5). Based on our estimated structure of the global GAS population, these reference genomes 201 
represent 27 previously unsampled phylogroups (Fig. 1a).  These high quality geographically, 202 
clinically and evolutionary diverse genomes will act as an important reference tool for vaccine 203 
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developers, microbiologists, and molecular biologists for new studies into the context of global 204 
GAS genome evolution, transmission and disease signatures. 205 
 206 
To further assess the relative contribution of recombination on individual phylogroups, we 207 
quanitifed the genome-wide rate and fragment length of recombination within 36 of the most 208 
highly sampled phylogroups (constituting 1,062 genomes). The microevolution of each lineage 209 
was assessed by mapping to a phylogroup specific reference genome and recombination 210 
assessed by Gubbins20, a tool previously shown to exhibit high concordance with other 211 
recombination detection approaches21.  The average number of SNPs observed within the 36 212 
phylogroups was 5,536 SNPs (range 191 to 24,899 SNPs) of which an average 20.5% of SNPs 213 
(range of 0.1 to 100%) were found to be vertically inherited within a phylogroup 214 
(Supplementary Table 6). Overall the ratio of recombination derived mutation versus vertically 215 
inherited mutation (r/m) was found to be 4.95 (median of 3.12), and noteably, is significantly 216 
greater than 1 (one-sample Wilcoxon test p-value of 7 x 10-7) suggesting that recombination is 217 
the primary driver of SNP derived variation in GAS (Supplementary Fig. 8). The average 218 
number of recombination events per phylogroup was found to be 58.94 (range 0 to 299) 219 
(Supplementary Table 6). Plotting the length of recombination blocks/fragments revealed that 220 
the majority of the events were small in length (< 5000bp) with large events occurring 221 
infrequently (Supplementary Fig. 9). The average recombination fragment length in each of 222 
the 36 phylogroups was 5,437 bp, ranging from 0 bp (phylogroup 23) to 101,894 bp 223 
(phylogroup “0”). Removal of recombination events associated with putative mobile genetic 224 
elements had a limited effect on the total number of recombination events per phylogroup 225 
(Supplementary Fig. 9), suggesting that hertitable heterogeneity is largely mobile genetic 226 
element (MGE) independent. These data highlights that evolution across the core genome of 227 
11 
 
GAS lineages is not uniform and is primarily driven by small homologous recombination 228 
events. 229 
 230 
Analysis of the variable gene content (defined as protein coding genes present in less than 99% 231 
of the 2,083 genomes) across the entire 2,083 genomes identified 3,672 ‘accessory’ genes when 232 
homologues were clustered at a conservative 80% amino acid identity using Roary22 (average 233 
of 1,717 protein coding genes per genome). Plotting of unique protein counts per new genome 234 
added shows that GAS has an ‘open’ pangenome (Fig. 1b), indicating that further genes will 235 
continue to be identified as new GAS genomes are sequenced. Annotation of the accessory 236 
genome derived from prophage analysis of the draft genome assemblies estimated ~50% of the 237 
accessory gene pool of GAS to be phage related. Plotting of the accessory content relative to 238 
the core genome phylogenetic structure of the global population revealed extensive variation 239 
both in total overall, and prophage content within and between, GAS core genome lineages 240 
(Supplementary Fig. 10), in-line with observations from GAS microevolutionary analyses23-26. 241 
Collectively, this high level of heterogeneity both in the context of core genome sequence and 242 
accessory gene content provides a unique database for the examination of disease signatures as 243 
well as exploring conservation and sequence variation within GAS proteins such as vaccine 244 
antigens. 245 
 246 
Disease signatures within global GAS database 247 
The lack of correlation between evolutionary lineages and clinical association such as invasive 248 
infection, suggests that disease propensity is not restricted to an evolutionary lineage or clone. 249 
The interrogation of genomic databases enables an assessment on whether there are common 250 
genetic factors over-represented with a clinical phenotype, within a globally disseminated 251 
genetically diverse bacterial population. Invasive propensity in GAS has been linked with a 252 
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number of bacterial genetic factors and regulatory mutations2,27. To ascertain statistical support 253 
of gene content, gene polymorphisms or combinations thereof with clinical GAS invasiveness 254 
within this global genomic framework, we used the bacterial GWAS method of pyseer73. In 255 
this study, we defined invasiveness as those GAS isolated from a normally sterile site (blood, 256 
cerebrospinal fluid, bronchopulmonary aspirate) or severe cellulitis with positive GAS culture 257 
as invasive (n = 1,048); and those from clinical superfical infections such as throat, skin or 258 
urine as non-invasive (n = 896).  We included country of origin as a regression covariate, to 259 
correct for geographical bias as previously defined27. Through this approach, we identified 184 260 
hits provisionally associated with GAS invasiveness. Even though it was corrected for, at this 261 
significance level population structure confounding effects were apparent (which cause 262 
associations at the same p-value across the entire genome) (Supplementary Fig. 11). The top 263 
five k-mers which exceeded this threshold include a GAS virulence marker isp (immunogenic 264 
secreted protein)28; a LacI family transcriptional regulator; and a hypothetical open reading 265 
frame neighbouring the cysteine protease speB (Supplementary Table 7). Further studies are 266 
required to ascertain a link between genotype and an invasive phenotype. This analysis 267 
demonstrates the utility of the global database for generating new disease insights. 268 
 269 
GAS vaccine target variation 270 
To examine natural variation of proposed GAS vaccine antigens within this genetically diverse 271 
GAS population, antigen carriage (gene presence/absence) and amino acid sequence variation 272 
of 29 proteinaceous GAS antigens, including 4 peptide fragments, was determined 273 
(Supplementary Table 1). The list of identified vaccine antigens analysed in this study have all 274 
been shown to convey protection in various murine models (reviewed by Henningham et al. 275 
20126) but little is known about the conservation of these antigens within the global GAS 276 
population. Applying a sequence homology-based screening approach to the 2,083 GAS 277 
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genome assemblies, 13 antigen genes were identified in >99% of isolates (Fig. 2a) at a 70% 278 
BlastN cut-off. The group A carbohydrate antigen is derived from a 12 gene biosynthetic 279 
cluster (gac) that has displayed protective properties in an animal model13. 2,017 GAS genomes 280 
(97%) shared all 12 protein coding genes with high DNA sequence conservation. Some 281 
genomes harboured frameshift mutations in several gac genes suggesting that not all 12 genes 282 
are critical for GAS survival, commensurate with previous findings on 520 gac loci29. 283 
 284 
In addition to being omnipresent within the GAS population, an ideal GAS vaccine candidate 285 
would exhibit low levels of naturally occurring sequence variation within a genetically diverse 286 
dataset. To examine this question, pairwise BlastP cut-off values for 25 protein antigens were 287 
calculated. Eighteen antigens exhibited low levels (<2%) of amino-acid sequence variation 288 
(Supplementary Fig. 12). When plotted relative to overall carriage within 2,083 genomes, 13 289 
of the 25 antigens were not only carried by >99% of the 2,083 genome sequences but also 290 
exhibited low levels of allelic variation (<2% sequence divergence) (Fig. 2b, Supplementary 291 
Fig. 12). Furthermore, 11 of these 14 core genome vaccine antigens were identified to have 292 
signatures of homologous recombination in their evolutionary history (Supplementary Fig. 13). 293 
The highest level of sequence heterogeneity in pre-clinical vaccine antigens was observed 294 
within the M-protein. Collectively 33% of genomes had an N-terminal emm sub-type (685 out 295 
of 2,083) represented within the 30-valent M-protein vaccine formulation30 (Fig. 2a). We also 296 
examined the prevalence of other GAS peptide-based vaccine antigens, namely the C-terminal 297 
M-protein sequences of J831 and StreptInCor32; and the S2 peptide from the serine protease 298 
SpyCEP33. Given conformational and binding constraints afforded by peptide vaccine antigens 299 
relative to the complete protein antigens investigated above, carriage of these peptide antigens 300 
were assessed at an exact 100% match with the query peptide sequence within the 2,083 GAS 301 
genomes. 37% of the 2,083 isolates harboured the J8.0 allele of the M-protein; 17% carry the 302 
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conserved overlapping B and T cell epitope of the StreptInCor M-protein vaccine candidate; 303 
and 56% of isolates encode the S2 peptide from SpyCEP protein. Further interrogation of 304 
known J8 sequence variants within the multi-copy M- and M-like C-repeat sequences 305 
represented in the 2,083 genome assemblies identified carriage of J8.12 (79%) and J8.40 (76%) 306 
to be the most frequently encountered variants (Supplementary Fig. 14).  307 
 308 
The identification of high homoplasy across core GAS antigens, including proposed vaccine 309 
antigens, emphasises that the evolution of GAS gene products is likely to be an ongoing process 310 
driven by recombination, genetic drift and diversifying selection. The characterisation of core 311 
gene products under different selection pressures may be used to identify putative vaccine 312 
antigen targets. Using the ratio of non-synonomous to synonomous codon subsititutions (dN/dS 313 
ratio) of each of the non-recombinogenic 416 genes, we identify that the average dN/dS ratio 314 
across the core GAS genome is greater than expected under a neutrality ratio of 1 (1.16), 315 
consitituing 49% of core genes (205 out of 416), suggestive of an overall positive selection 316 
across the GAS genome (Supplementary Table 4). Of the 3 ‘non-recombinogenic’ core vaccine 317 
targets analysed in this study, the streptococcal hemoprotein receptor (Shr) had signatures of 318 
positive selection (dN/dS 1.22) while the hypothetical membrane associated protein Spy0762 319 
and the nucleoside-binding protein Spy0942 both exhibited signatures of purifying selection 320 
with dN/dS ratios of 0.57 and 0.66 respectively (Supplementary Table 4).  321 
 322 
Antigenic heterogeneity within GAS vaccine antigens 323 
Structural analysis of antigens through protein crystallography yields insights regarding the 324 
identification of key functional amino acid residues and juxtaposition of surface peptide 325 
sequences. The ascertainment of antigenic variation within genome sequence databases allows 326 
such data to be overlaid onto protein structures, yielding important insight regarding potential 327 
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sites of structural plasticity or immunodominance, that in turn can be used to inform vaccine 328 
design through identification of invariant surface regions and/or structurally constrained 329 
domains or subdomains. Two crystal structures are publically available for GAS proteins that 330 
fulfil the criteria of global vaccine antigen coverage as defined in this study (>98% carriage 331 
and <2% amino acid sequence variation): Streptolysin O34 and C5a peptidase35. Identification 332 
of polymorphism location and polymorphism frequency within the 2,083 GAS genomes for 333 
the Streptolysin O (Fig. 3a, Supplementary Table 8) and C5a peptidase (Fig. 3b, Supplementary 334 
Table 9) proteins were determined. Using this data, we derived the consensus amino acid 335 
sequence for each protein. We then modelled the consensus sequence and population derived 336 
polymorphisms onto the corresponding crystal structures of the mature Streptolysin O protein 337 
(amino acids 103-501, Fig. 3b, c)34 and C5a peptidase (amino acids 97-1032; Fig. 3b, d)35. 338 
Using data extracted from the 2,083 genomes, further examination of amino acid heterogeneity 339 
present within the mature Streptolysin O protein revealed 5 sequence diversity hotspots (Fig. 340 
3c). All hotspot polymorphisms were bimorphic in nature indicating restrictions in Streptolysin 341 
O plasticity (Supplementary Table 10). In comparison, we identified 20 sequence diversity 342 
hotspots within the mature C5a peptidase protein of which half were bimorphic (Fig. 3a, 343 
Supplementary Table 11), indicating more plasticity can be accommodated within the C5a 344 
peptidase than Streptolysin O. To ascertain the functional consequence of the most common 345 
protein variations, we examined mutational sensitivity and structural integrity of these amino 346 
acids variants using Phyre236 and the SuSPect platform37.  All substitutions in both Streptolysin 347 
O and C5a peptidase were at locations where it was predicted that a change to any amino acid 348 
would not impact protein structure or activity (Supplementary Tables 10 and 11).  To further 349 
examine selective pressures within these antigens, we assessed the selective constraints at each 350 
codon position. We found that 10.5% (60/571) of amino acid residues had higher diversity at 351 
first and second codon positions than at third codon positions for Streptolysin O and 16.5% 352 
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(170/1032) for C5a peptidase, indicating that these sites are undergoing positive selection 353 
(Supplementary Tables 8 and 9). Of these sites with signatures of positive selection, 40% (2/5) 354 
were diversity hotspots for Streptolysin O and 60% (12/20) for C5a peptidase.  These data may 355 
reflect immune selection and/or the amount of plasticity that can be encompassed without 356 
compromising protein function. 357 
 358 
DISCUSSION 359 
There is a strong case for the development of a safe and efficacious GAS vaccine1,2. One of 360 
several hurdles to be addressed in the development of a GAS vaccine suitable for worldwide 361 
use is the extensive genetic diversity of the global GAS population. To address issues of 362 
vaccine antigen gene carriage within the global GAS population and the extensive variation of 363 
antigen amino acid sequences between isolates, we have developed a platform for the 364 
interrogation of candidate antigens at unprecedented resolution. We have demonstrated that 365 
GAS is a genetically diverse species containing a large dispensable gene pool. Within the core 366 
or ‘conserved’ genome we have identified extensive evidence of recombination that will 367 
initiate future research into the biology and underlying drivers of such dynamic evolution. This 368 
diversity also has consequences for vaccine induced evolutionary sweeps of bacterial 369 
populations and subsequent emergence of vaccine escape clones, as has been observed in 370 
targeted Streptococcus pneumoniae38 and Bordetella pertussis39 vaccination programs. Our 371 
findings identify that selection pressures are variable across the core GAS genome and 372 
proposed vaccine candidates, likely reflective of distinct and ongoing evolutionary adaptation. 373 
Collectively, within an evolving global bacterial pathogen such as GAS, we have identified 374 
that a number of proposed pre-clinical GAS vaccine antigens fulfil the criteria for a global 375 
vaccine. It is tempting to speculate that multi-antigenic formulations would provide an ideal 376 
approach against a rapidly evolving pathogen as well as increasing global coverage. Indeed, 377 
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the incorporation of additional antigens to existing serotype-specific approaches in GAS 378 
enhances theoretical vaccine coverage40 (Supplementary Table 12). 379 
 380 
We reveal that the global population structure of GAS is one of extensive genetic diversity, 381 
likely to be reflective of rapid international spread of genetically diverse lineages driven by 382 
diversifying selection from the immune system and/or competition between lineages. This may 383 
lead to negative frequency dependant selection as has been proposed for other human bacterial 384 
pathogens such as S. pneumoniae and E. coli41,42. Recombination has previously been identified 385 
to be high in GAS43,44 and at a genome-wide population level, our findings suggest a major 386 
role for homologous recombination of small DNA fragments in driving the evolutionary 387 
dynamics of GAS, indicating that evolution of GAS lineages is more likely to arise by 388 
recombination rather than by mutation43. All GAS lineages do not evolve at the same rate and 389 
this is likely to have key, yet undefined, biological significance. Similar impact and rates of 390 
homologous recombination have been observed in other bacterial pathogens such as S. 391 
pneumoniae45 and Legionella pneumophila46. A comparison of the relative rates of 392 
recombination versus mutation, based on whole-genome and gene-restricted MLST 393 
approaches, places S. pyogenes with other highly recombinogenic species such as K. 394 
pneumoniae and S. pneumoniae (Table 1). 395 
  396 
The generation of high quality, well curated reference genomes acts as a landmark for 397 
understanding the evolutionary context of a species, especially given the high levels of genetic 398 
diversity encountered in bacterial populations such as GAS and the contrasting epidemiology 399 
of infection observed between high-income countries and less-developed economic regions of 400 
the world where the overwhelming burden of GAS disease resides. The availability of new 401 
GAS reference genomes will enable targeted evolutionary and pathobiological studies of this 402 
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genetically diverse pathogen. The 30 new GAS reference genomes reveal that despite an open 403 
pangenome where accessory gene content varies significantly across the population and 404 
recombination appears frequent, the overall size of the GAS genome remains at a steady state. 405 
Only recently have plasmids been characterized within the GAS genome47,48. We have 406 
identified a further 5 small plasmids in GAS ranging in size from 2,645 bp to 6,485 bp, 407 
harbouring bacteriocin-like genetic markers that are suggested to play a role in inter-bacterial 408 
inhibition49. In the context of vaccination, the availability of a globally representative reference 409 
database will provide a platform for examining the effect of future vaccination programs38,39.   410 
 411 
Modelling of population based antigenic variation against protein crystal structures enables the 412 
identification of residues that may be under functional or structural constraints, or alternatively, 413 
selection pressure. This population-derived sequence approach could be assessed alongside 414 
immunological studies to define protective epitopes. Such information can be incorporated into 415 
further refinement of vaccine antigens such as peptide-based approaches that factor in naturally 416 
occurring population heterogeneity, enabling the targeting of immunogenic epitopes within 417 
antigens that are less amenable to variation.  418 
 419 
This platform for population genomics-informed vaccine design is equally applicable to all 420 
known GAS antigens and those that remain to be discovered. Thus, informed selection of 421 
putative vaccine antigens for human trial evaluation will now be possible, allowing 422 
identification of highly conserved antigens or combinations of antigens that ensure complete 423 
vaccine coverage across GAS emm types from differing geographic regions. For example, GAS 424 
vaccine antigens such as SLO, SpyCEP, ADI, TF and C5a peptidase, found here to be highly 425 
conserved across geographic regions, protect against multiple GAS emm types in animal 426 
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models14,50,51. An approach similar to that used in this study would also be applicable to other 427 
pathogens that exhibit high levels of global strain diversity. 428 
 429 
  430 
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FIGURE LEGENDS 611 
 612 
Figure 1. Population structure and pangenome of 2,083 globally distributed GAS strains. (a) 613 
Maximum-likelihood phylogenetic tree of 30,738 SNPs generated from an alignment of 416 614 
core genes. Branch colours indicate bootstrap support according to the legend. Distinct genetic 615 
lineages (n = 299) are highlighted in alternating colours (blue and grey) from the tips of the 616 
tree. Coloured asterisks refer to the relative position of complete GAS reference genome 617 
sequences (existing references are shown in brown; 30 new reference genomes are shown in 618 
dark blue). Colour coded around the outside of the phylogenetic tree is the country of isolation 619 
for each isolate. (b) Pangenome accumulation curve of 2,083 GAS genomes based on 620 
clustering of protein sequence at 70% homology.  621 
 622 
Figure 2. Antigenic variation within vaccine targets from 2,083 GAS genomes. (a) Gene 623 
carriage (presence/absence) of vaccine antigens. (b) Amino acid sequence variation within 25 624 
protein antigens for each of the 2,083 GAS genomes. Each ring represents a single antigen with 625 
protein similarity colour coded according to pairwise BlastP similarity: Black (>98%); Blue 626 
(between 95 – 98%); Red (between 90 - 95%); Pink (80 - 90%); Yellow (70 - 80%); Grey (< 627 
70%); and White (protein absence). Rings correspond to: 1) R28; 2) Sfb1; 3) Spa; 4) SfbII; 5) 628 
FbaA; 6) SpeA; 7) M1 (whole protein); (8) M1 (180bp N-terminal) 9) SpeC; 10) Sse; 11) 629 
Sib35; 12) ScpA; 13) SpyCEP; 14) PulA; 15) SLO; 16) Shr; 17) OppA; 18) SpeB; 19) Fbp54; 630 
20) SpyAD; 21) Spy0651; 22) Spy0762; 23) Spy0942; 24) ADI; and 25) TF. 631 
 632 
Figure 3. Global amino acid variation mapped onto the protein crystal structure of the mature 633 
GAS Streptolysin O34 and C5a peptidase35.  (a) Frequency of amino acid variations within 634 
2,083 genomes. (b) Schematic of the Streptolysin O and C5a peptidase open reading frame 635 
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representing the location of amino acids within the mature enzymes (blue block). Model of the 636 
consensus sequence of the Streptolysin O (c) and C5a peptidase (d) mature enzymes. Plotted 637 
against the structure is the amino acid variation frequency within the 2,083 GAS genomes as 638 
represented in the colour gradient from 1% variable (blue) to 42% variable (red); invariant sites 639 
are coloured in light grey. Position of the top 5 most variable surface hotspots (“HS”) are 640 
annotated (as defined in Supplementary Tables 10 and 11). Active sites for each enzyme are 641 
indicated (cyan arrow).  642 
 643 
Table 1. Comparative ratio of nucleotide changes resulting from recombination relative to 644 
point mutation (r/m) in selected bacterial pathogens  645 
 646 
Species r/m ratio 
(genome-wide) 
r/m ratio  
(MLST-derived)* 
References 
Streptococcus 
pyogenes 
4.95 17.2  This Study and Enright 
et al4 
Streptococcus 
pneumoniae 
6.36 23.1 Chaguza et al52,53 
Staphylococcus 
aureus 
0.6  0.1 Driebe et al,54,55 
Legionella 
pneumophilla 
47.8 0.9 David et al46,56 
Klebsiella 
pneumoniae 
4.75 0.3 Diancourt et al57,58 
Footnotes 647 
*Multi-locus Sequence Type (MLST) allele-derived r/m ratios as defined by Vos and Didelot44. 648 
  649 
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ONLINE METHODS  650 
 651 
Bacterial isolates  652 
The global collection of 2,083 Streptococcus pyogenes isolates examined in this study included 653 
short read genome sequence data from population-based studies that we have generated within 654 
Kenya59 and Fiji27, and other disease specific population-based studies of invasive GAS from 655 
Canada60, USA19 and the United Kingdom61,62 that was available as of 1st July 2018. We 656 
selected a small subset of isolates from published microevolution (outbreak) studies to avoid 657 
biasing the collection on single genetically related lineages. Sixty-eight GAS reference 658 
genomes and publically available draft genomes from Lebanon63 were also included. To 659 
increase genomic representation from regions endemic for GAS infection and other under-660 
sampled geographical regions, we collected a further 271 isolates from Australia, 279 isolates 661 
from New Zealand, 50 isolates from Brazil, 45 isolates from India and 7 isolates from Belgium. 662 
The rationale underpinning isolate selection was difference in epidemiological markers (emm 663 
type), anatomical site of isolation (skin, throat, blood) and clinical presentation, all key factors 664 
in GAS vaccine design. Metadata pertaining to the database of isolates are provided in 665 
Supplementary Table 2.  666 
 667 
Genome sequencing and assembly 668 
Genomic DNA was extracted and paired-end multiplex libraries were created and sequenced 669 
using the Illumina Hi-seq 2500 platform at the read-length between 75 to 125 bp (Wellcome 670 
Trust Sanger Institute, UK). Draft genome sequences were generated using an iterative Velvet-671 
based assembly pipeline with secondary read mapping validation64 or using SKESA v2.3.065 672 
with default parameters. Gene predictions and annotations were generated using PROKKA66 673 
and streptococcal RefSeq specific databases64. Annotations pertaining to the mga locus 674 
28 
 
(including emm and emm-like genes) were manually curated using in-house databases due to 675 
ambiguity when using pipeline procedures. The assembly pipeline generated assemblies of an 676 
average length of 1,791,171 bp (range 1,641,039 bp – 1,986,343) and an N50 of 252,789 bp 677 
(range 2,276 – 1,953,601 bp). On average, 1,711 coding sequences were identified per draft 678 
genome (range 1,495 – 1,976 coding sequences [CDS]). All draft genome assemblies are 679 
publically available through GenBank. Accession numbers are listed in Supplementary Table 680 
2. 681 
 682 
Sequence mapping 683 
To examine the genetic relationship of the 2,083 GAS genome sequences, we employed a 684 
single reference based mapping approach using sub-sampled Illumina fastqs at an estimated 685 
coverage of 75x. Published reference and draft genome datasets accessed from public databases 686 
were each shredded into an estimated 75x coverage of paired-end 100 bp reads using SAMtools 687 
wgsim. Sequence reads were mapped to the M1 GAS reference genome MGAS5005 (GenBank 688 
accession number CP000017)67 with BWA MEM (version 0.7.16) and read depth calculated 689 
with SAMtools (version 1.6) with a Phred quality score ≥20. Single nucleotide polymorphism 690 
(SNPs) with a Phred quality score ≥30 were identified in each isolate using SAMtools pileup 691 
with a minimum coverage of 10x. Core genes were defined as a minimum 80% of the 692 
MGAS5005 reference gene with a minimum 10x coverage. Using this approach, we identified 693 
1,306 MGAS5005 genes with 99% carriage in 2,083 genomes. A core SNP genome alignment 694 
of 171,273 SNPs was generated by concatenating the SNPs located within the 1,306 core genes, 695 
giving a total of 1,201,767 bp. SNPs residing within repeat regions (minimum length of 20 696 
nucleotides) and mobile genetic elements are considered evolutionary confounders and were 697 
identified as previously described68 or identified using PHASTER69. SNPs within these regions 698 
were excised from the core alignment, reducing the length from 1,201,767 bp to 1,197,326 bp 699 
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and the SNP count from 171,273 to 170,653. Therefore, a total of 170,653 SNPs were aligned 700 
for phylogenetic analysis of the 1,306 ‘core’ genome (Supplementary Fig. 3).  701 
 702 
Recombination detection 703 
To examine evidence of recombination within the core GAS genome, FastGEAR17 was run on 704 
1,306 individual gene alignments, comprising all 2,083 GAS strains included in the study. This 705 
method infers population structure for each alignment allowing for detection of lineages that 706 
have ancestral and recent recombinations between them. Default parameters were used with a 707 
minimum threshold of 4 bp applied for recombination length. A total of 890 genes had 708 
signatures of recombination and were excluded from evolutionary analyses. The remaining 416 709 
genes were concatenated, corresponding to 268,003 bp of sequence. SNPs residing within 710 
repeat regions were removed as described above, resulting in 266,960 bp of sequence used as 711 
a best estimate for the global GAS population structure. 712 
  713 
For intra-phylogroup recombination analyses, 36 most highly represented PopPunk 714 
phylogroups were chosen to investigate the influence of recombination (1,062 isolates).  For 715 
each phylogroup, core genome alignments were performed using Snippy v4.3.5 716 
(https://github.com/tseemann/snippy), against a reference strain within each phylogroup 717 
(Supplementary Table 6), maximum likelihood trees were inferred using IQtree v1.6.570, which 718 
were used as inputs for the recombination detection tool Gubbins v.2.3.420. Gubbins was run 719 
with maximum number of iterations of 20 with the minimum number of 5 SNPs to identify a 720 
recombination block, with a window size of 100 to 10,000 bp, with any taxa with more than 721 
25% gaps filtered from the analysis. Recombinogenic blocks that overlapped with predicted 722 
mobile genetic elements (MGEs) in the reference genome were discarded. Phage regions were 723 
determined using PHASTER69 and integrative conjugative elements (ICE) were determined by 724 
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manual inspection of reference genomes based on similarity of blast hits from known ICE. 725 
Recombination versus vertically inferited mutation (r/m) ratios for each lineage were 726 
calculated as the average r/m including all isolates within the phylogroup. For the species 727 
values of r/m was determined by the average across all 36 phylogroups (Table 1).  728 
 729 
Phylogenetic analysis 730 
Maximum-likelihood trees were generated for the 416 and 1,306 core genome alignments using 731 
IQ-tree v1.6.570. The generalized time-reversible nucleotide substitution with gamma 732 
correction for site-specific rate variation was performed with 100 bootstrap random 733 
resampling’s of the alignment data to support for maximum-likelihood bipartitions. For figure 734 
generation, phylogenetic trees and associated metadata were collated using the web portal, 735 
Interactive Tree of Life71.  736 
 737 
Population genomics and cluster designation 738 
To define evolutionary related clusters (phylogroups) in the population we used PopPUNK 739 
(Population Partitioning Using Nucleotide K-mers), which has previously been shown to give 740 
high quality clusters in a subset of S. pyogenes isolates included in this study18. We used k-741 
mers between 15 and 29 nucleotides long in steps of two to calculate core and accessory 742 
distances between all pairs of isolates (Supplementary Fig. 4a). We clustered these distances 743 
first with the default two-component Bayesian Gaussian Mixture Model, then used the 'refine 744 
fit' mode to move the boundary of this fit such that the network was highly transitive and sparse, 745 
obtaining a network score (ns) of 0.980 (Supplementary Fig 4b, c). To increase the utility of 746 
the GAS population clusters defined here, we created a database so that others can assign 747 
sample clusters using the same model and nomenclature as we present here. To do this we used 748 
PopPUNK to extract one sample per clique in the network, giving a reduced size query database 749 
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containing 359 sequences. This database can be accessed 750 
at https://doi.org/10.6084/m9.figshare.6931439.v1 and contains an example command for 751 
database query and future expansion. The PopPUNK cluster designation (“phylogroup”) for 752 
each of 2,083 genomes have been added to Supplementary Table 2 and to the Microreact79 753 
interative web application (rJbD5w2nZ). 754 
 755 
Nucleotide divergence was derived by calculating the pairwise hamming distance from the 416 756 
core genome alignment (266,960 bp). For pairwise hamming distance plots based on 757 
epdemiological markers (Supplementary Fig. 7), a reference genome was assigned for each 758 
marker based on the most representative distance within each type (minimum combined 759 
hamming distance) from the 416 core genome alignment.  760 
 761 
Pangenome analysis 762 
The pangenome was defined using Roary v3.11.222 without splitting paralogs and with 763 
clustering at 80%. Accessory genome was defined as the pan less the core, totalling 3,672 764 
genes. Identification of prophage CDS within each of the 2,083 genomes was performed using 765 
PHASTER69. Clustering with CD-HIT-EST72 at ≤90% nucleotide homology resulted in 1,438 766 
gene clusters. 584 core genes and 1,567 accessory genes hit these phage regions with blastn 767 
v2.3.0+ with a 90% nucleotide cut-off over 90% of the gene length. These data were then 768 
processed to generate a binary gene content matrix in which the presence of a gene is defined 769 
as >90% coverage to a corresponding phage gene cluster. 770 
 771 
Vaccine antigen screening pipeline 772 
To examine naturally occurring antigenic variation of proposed GAS vaccine targets within 773 
this genetically diverse GAS population, carriage of 29 vaccine antigens (Supplementary Table 774 
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1) and the group A carbohydrate biosynthesis loci was determined. The list of vaccine antigens 775 
screened have been shown to convey a significant level of protection in murine models6, but 776 
less is known about the conservation of these antigens within a global context. The presence 777 
of vaccine antigen genes was determined by BlastN analysis of 2,083 genome assemblies based 778 
on a 70% nucleotide cut-off over 70% of the gene length. N-terminal emm peptide and whole 779 
emm protein were extracted using publicly available databases to account for known higher 780 
levels of allelic variation. This data was then converted into a binary gene content matrix in 781 
which gene presence was defined as >70% homology across a minimum 70% of the query gene 782 
length. Allelic variation was examined by plotting tBlastN (or BlastN for group A carbohydrate 783 
genes) scores relevant to the query reference sequence. To facilitate future studies assessing 784 
vaccine antigen carriage and sequence variation within GAS genome sequences, we have 785 
generated a bioinformatics pipeline for assessing antigenic variation from genome assemblies. 786 
This script, as used in this study, is available at 787 
https://github.com/shimbalama/screen_assembly and requires a query sequence (such as a 788 
vaccine antigen) and will run BlastN, tBlastN or BlastP at a user defined cut-off generating 789 
numerous outputs and plots as represented in this study (see Fig. 3a, Supplementary Fig. 12 790 
and Supplementary Tables 8 and 9). Futhermore, this screening approach is applicable to any 791 
pathogen where genome assemblies are supplied.  792 
 793 
Streptolysin O and C5a peptidase surface variation 794 
Protein sequences of streptolysin O and C5a peptidase were chosen for further analyses as well 795 
characterised crystal structures exist for each of these GAS antigens. A protein alignment 796 
corresponding to the published crystalised structures of streptolysin O (amino acid residues 797 
103 – 571, Protein Data Bank [PDB] accession number 4HSC34) and C5a peptidase (amino 798 
acid residues 97 - 1032, PDB accession number 3EIF35) was generated. Using this data, we 799 
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derived the consensus amino acid sequence for each protein as defined by the most common 800 
amino acid identified within the global GAS genome database and modelled the consensus 801 
against the mature crystal structures. Amino acid polymorphic sites were converted into a 802 
binary matix and presented as a percentage of 2,083 genomes in Fig. 3. Visualisation of 803 
polymorphic sites on the crystal structure was determined using Chimera (version 1.11.2)73.  804 
Mutational sensitivity and structural integrity analyses was performed using Phyre236 that 805 
incorporates the SuSPect platform37. 806 
 807 
Signatures of molecular adaptation  808 
We investigated molecular signatures of selective constraints in all non-recombinogenic core 809 
genes (n = 416) by fitting a codon model to each of the individual genes and estimating the 810 
ratio of synonymous to nonsynonymous substitutions, dN/dS (also known as ω). 811 
Recombinogenic core genes (n = 890), as identified by fastGEAR, were excluded from 812 
analyses as such evolutionary processes invalidate phylogenetic codon model fitting. For each 813 
gene alignment, ambiguous codon sites were first excluded, before fitting the M0 codon model 814 
in CODEML, part of the PAML v4.0 package74. This model estimates a global dN/dS which 815 
allows for straight-forward comparison between genes. For the Streptolysin O and C5a 816 
peptidase protein coding genes we conducted more detailed analyses, by assessing selective 817 
constraints across codon sites. To do this we counted the number synonymous and 818 
nonsynonymous substitutions in each codon position, to obtain a similar quantity to the dN/dS 819 
value above75. Although this method does not explicitly use a codon model, it is scalable for 820 
the large number of samples used here. Despite the objective of this study being centered 821 
around global diversity, our database does contain sample bias in the context of clinical and 822 
geographical sampling, and the selection analyses should be interpreted carefully, as they may 823 
not represent current global selective trends. 824 
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 825 
Generation of 30 new GAS reference genomes 826 
The vast majority of publically available completely sequenced reference genomes are of emm-827 
types from North America and Europe and very few are of emm-types from high-disease 828 
burden geographical regions. To facilitate the expansion of studies within the highest disease 829 
burden regions, 30 isolates were completely sequenced using long-read sequencing 830 
technology. Long-read sequences were obtained using the Pacific Biosciences RS II platform 831 
from a single molecule real-time (SMRT) cell as described previously76. Briefly, genome 832 
sequences were assembled using the SMRTpipe version v2.1.0 using the Hierarchical Genome 833 
Assembly Process (HGAP.2) and Quiver for post-assembly consensus validation. Secondary 834 
validation of the assemblies was performed using the Canu assembler77. To correct long-read 835 
sequence errors, primarily around homopolymeric regions, Illumina short read sequences from 836 
each of the 30 genomes were mapped using BWA MEM v0.7.16. Single contigs were achieved 837 
for all genomes and associated plasmids where present, with an average coverage depth of 80x. 838 
Genomes were annotated using the same pipeline as for the Illumina draft genomes64 with 839 
putative prophage regions defined using the PHASTER server69. 840 
 841 
Genome-Wide Association of GAS Invasiveness 842 
To identify genomic signatures within the global GAS population overrepresented with severe 843 
GAS infection (‘invasive’) we ran pyseer78 on 1,944 samples (1,048 defined as invasive) using 844 
the linear mixed model.  A total of 87M k-mers between 9 and 100 bases long were counted 845 
using fsm-lite. We only tested common k-mers, those with a minor allele frequency >1% (of 846 
which 18M were counted in our dataset). We created a kinship matrix from our recombination-847 
free core phylogenetic tree of 2,083 genomes (416 genes, Figure 1a). The country of isolation 848 
was used as a covariate in pyseer’s model to account for geographical signal as defined 849 
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previously27. All k-mers were mapped to the MGAS5005 GAS reference genome using bwa 850 
and visualised with R. We used a Bonferroni correction to adjust the significance threshold 851 
passed the number of unique patterns tested, which gave 9.4x10-7 for a 0.05 family-wise error 852 
rate. 184 k-mers were significantly associated with severe infection. 853 
 854 
Data Availability 855 
Illumina sequence reads and draft genome assemblies were deposited into the European 856 
Nucleotide Archive under the accession numbers specified in Supplementary Table 2. Genbank 857 
accession numbers for the 30 new GAS reference genomes are provided in Supplementary 858 
Table 5. To facilitate community accessibility and interrogation of the data presented in this 859 
study, the phylogenetic (Fig 1a), PopPUNK phylogroup designations, and associated metadata 860 
components have been uploaded to the interactive web interface Microreact79 (identification 861 
number rJbD5w2nZ). The PopPUNK database for assigning new genomes is available at 862 
https://doi.org/10.6084/m9.figshare.6931439.v1. 863 
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 1078 
SUPPLEMENTARY FIGURE LEGENDS 1079 
 1080 
Supplementary Figure 1. Recombination analysis of 890 recombinogenic core GAS genes. 1081 
Maximum-likelihood phylogenetic tree of core global GAS genome (416 ‘non-1082 
recombinogenic’ genes; 30,738 SNPs) is shown on the left. Middle panel shows fastGEAR17 1083 
outputs where each gene was analysed independently with recombinations coloured by donor 1084 
lineage for each gene. Yellow is used to represent the most frequent lineage for each gene to 1085 
optimise visualisation. Homologous recombination blocks are represented as gene fragments 1086 
harbouring multiple ‘colors’. The plot on top shows the number of homologous recombination 1087 
events detected per gene.  1088 
 1089 
Supplementary Figure 2. Support for the core genome phylogeny. Correlation between 1090 
private SNPs (i.e. SNPs unique to each genome) and the length of the branch leading to that 1091 
genome in the maximum-likelihood phylogenetic tree (416 genes), displayed as a proportion 1092 
of the total length to the root. This correlation indicates that the raw SNP data supports the deep 1093 
branching observed in the phylogeny and this is not an artefact of enforcing a tree-like structure 1094 
onto the data. 1095 
 1096 
Supplementary Figure 3. Tanglegram comparison of maximum-likelihood phylogenetic tree 1097 
topologies based on the 1,306 gene core genome (left: 170,653 SNPs) and the 416 gene core 1098 
genome (right: 30,738 SNPs) after the removal of ‘recombinogenic’ genes.  Colours refer to 1099 
299 different PopPUNK phylogroupings. While the terminal clustering of the trees has not 1100 
changed after removal of ‘recombinogenic’ genes, recombination has distorted the ancestral 1101 
evolutionary signal within the core GAS genome. 1102 
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 1103 
Supplementary Figure 4. PopPUNK model fitting and refined network clustering of 2,083 1104 
GAS genomes. (a) Scatter plot showing core (π) and accessory (a) distance between all pairs 1105 
of isolates with density contours displayed. (b) Same scatter plot as (a) after network score fit 1106 
refinement for within cluster boundary. Blue points are distances comparing genomes within 1107 
the same phylogroup, turquoise points are distances comparing genomes in different 1108 
phylogroups. The red dashed line separates these assignments, grey dashed lines are the fit 1109 
using core and accessory distances only. These data suggest low within-strain recombination 1110 
(dense cluster of points near the origin of the graph), but high between-strain recombination 1111 
(single broad cluster of between-strain points). (c) Network assignment of refined 299 1112 
PopPUNK clusters where samples are nodes (coloured by assigned cluster) and edges are 1113 
pairwise links judged to be within the same cluster using the refined fit shown in (b). 1114 
 1115 
Supplementary Figure 5. Population structure of 2,083 GAS genomes based on (a) 299 1116 
phylogroups and (b) their clinical association. Maximum-likelihood phylogenetic tree of core 1117 
global GAS genome (416 genes) as displayed in Fig. 1. Branch colours indicate bootstrap 1118 
support according to the legend. Distinct genetic phylogroups (n = 299) are assigned a unique 1119 
colour to aid in visual designation of clusters in panel (a) while for each phylogroup in panel 1120 
(b) two alternate colours (blue and grey) are assigned (as in Fig. 1). 1121 
 1122 
Supplementary Figure 6. Population structure of 2,083 GAS genomes and their association 1123 
with primary GAS epidemiological markers. Maximum-likelihood phylogenetic tree of core 1124 
global GAS genome (416 genes) as displayed in Fig. 1. Branch colours indicate bootstrap 1125 
support according to the legend. Distinct genetic lineages (n = 299) are highlight in alternating 1126 
colours (blue and grey) from the tips of the tree. Represented from inner to outer rings of the 1127 
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epidemiological data are emm-type (n = 150), emm sub-type (n = 347), M-cluster (n = 39), and 1128 
MLST (n = 484).  1129 
 1130 
Supplementary Figure 7. Pairwise genetic (hamming) distance of the non-recombinogenic 1131 
GAS core genome (416 genes) based on isolates being of the same emm type (a); emm sub-1132 
type (b); MLST (c); M-protein cluster (d) and core genome PopPUNK phylogroups (d). Only 1133 
groups which contain multiple isolates are represented on the X-axis. For each group, one 1134 
reference was chosen based on having the mimimum median SNP distance from all other 1135 
samples in the group. Each dot indicates the genetic distance (number of nucleotide SNPs, Y-1136 
axis) of samples from this reference, blue (same phylogroup [evolutionary lineage] as the 1137 
reference), red (different phylogroup to the reference). 1138 
 1139 
Supplementary Figure 8. Box and whisker plot showing the ratio of recombination derived 1140 
mutation versus vertically inherited mutation (r/m) for the 36 most sampled phylogroups. 1141 
Overall the average r/m across these phylogroups was 4.95 (median of 3.12), and notably, is 1142 
significantly greater than 1 (p-value = 7 x 10-7 ), using a one-sample Wilcoxon test, with a test-1143 
value of 1.  1144 
 1145 
Supplementary Figure 9. Size distribution of intra-phylogroup recombination lengths. 1146 
Lengths of putative recombination blocks in a subset of the most highly sampled PopPUNK 1147 
phylogroups (n = 36 [total of 1,062 genomes]). Recombination blocks were defined using the 1148 
sliding window approach of Gubbins20 based on intra-phylogroup mapping. Cumulative 1149 
frequency of all recombination blocks within the 36 phylogroups including putative mobile 1150 
genetic elements (MGE) (a) or excluding putative MGEs (b) within a 5000 base pair (bp) 1151 
range. (c) Distribution of homologous recombination blocks (excluding MGE) within each of 1152 
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the 36 phylogroups (uniquely coloured) plotted from a 500 base pair sliding window (up to 1153 
20,000 bp). Collectively, evolution of GAS phylogroups is linked to high rates of small (<5000 1154 
bp) homologous recombination blocks.  1155 
 1156 
Supplementary Figure 10. Variation in the size and prophage content of the GAS accessory 1157 
genome. Counts of accessory genes per genome are overlaid against the maximum-likelihood 1158 
phylogenetic tree of core global GAS genome (416 genes) as displayed in Fig. 1. Branch 1159 
colours indicate bootstrap support according to the legend. Distinct genetic lineages (n = 299) 1160 
are highlight in alternating colours (blue and grey) from the tips of the tree. Red bars relate to 1161 
the total count of phage-related genes based on PHASTER analysis of the draft genome 1162 
assemblies and blue bars relate to ‘other’ genes. Accessory gene scale refers to the number of 1163 
genes (in 100 gene increments).  1164 
 1165 
Supplementary Figure 11. Manhattan plot of SNPs associated with invasive GAS infection. 1166 
The significance (y-axis) of each SNPs association with severe infection against its relative 1167 
position within the MGAS5005 genome (x-axis). The red line denotes a significance cutoff of 1168 
p < 9x10-7. Top five loci reaching significance (Supplementary Table 7) are annotated. 1169 
Associations were investigated by pyseer78 using k-mers with a minimum minor allele 1170 
frequency of 1%. 1171 
 1172 
Supplementary Figure 12. GAS vaccine antigen carriage (gene product) and sequence 1173 
variation within the 2,083 genome database. Left vertical axis refers to the bar graph showing 1174 
frequency of antigen carriage of 26 GAS vaccine antigens and the group A carbohydrate (GAC) 1175 
operon (X-axis) within 2,083 GAS genomes and the right vertical axis refers to the box and 1176 
whisker plot showing quartile range, median (red line) and minimum/maximum values of each 1177 
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antigen as inferred by BlastP (as per Fig. 2b). Generally, genes that are ’core’ have less 1178 
sequence heterogeneity than genes that are variably carried (accessory genes). 1179 
 1180 
Supplementary Figure 13. Recombination analysis of 11 conserved GAS vaccine antigens 1181 
within the context of 2,083 GAS genomes. Maximum-likelihood phylogenetic tree of core 1182 
GAS genome based on 416 non-recombinogenic genes of the 2,083 genomes is shown on the 1183 
left. Middle panel shows fastGEAR17 outputs per gene, with colours representing gene lineages 1184 
(as per Supplementary Fig. 1). The plot on top shows the number of homologous recombination 1185 
events detected per gene.  1186 
 1187 
Supplementary Figure 14. Frequency of J8 alleles in the GAS 2,083 genome database. 1188 
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Supplementary Table 1. Vaccine antigen candidates examined in this study^ and published status of vaccine development (shaded boxes). 
ANTIGEN 
Pre-
clinical Phase I Phase II 
Proof of 
concept Phase III Reference 
M protein: N-terminal peptide (30-valent)           Dale et al 2011
30 
M protein: C-terminal peptide (J8)           Batzloff et al 2003
31 
M1 protein: (whole protein)           Fox et al 1973
80 
M protein: C-terminal peptide (StreptInCor)      Guilherme et al 2006
32 
Trigger factor (TF)#           Henningham et al 2012
14 
Group A carbohydrate (GAC)           Sabharwal et al 2006
12 
C5a peptidase (ScpA)+#           Ji et al 1997
51 
Fibronectin-binding protein A (FbaA)           Ma et al 2009
81 
Fibronectin-binding protein 54 (Fbp54)           Kawabata et al 2001
82 
Streptococcal fibronectin binding protein I (SfbI)      Guzman et al 1999
83 
Serum opacity factor (SfbII/SOF)           Courtney et al 2003
84 
Streptococcal pyrogenic exotoxin A (SpeA)           Ulrich et al 2008
85 
Streptococcal pyrogenic exotoxin C (SpeC)           McCormick et al 2000
86 
Cysteine protease (SpeB)      Kapur et al 1994
87 
Serine protease (SpyCEP)*#      Zingaretti C et al 2010
88 
Serine protease (SpyCEP): S2 peptide            Pandey et al 2016
33 
Adhesion and division protein (SpyAD)+*      Bensi et al 2012
50 
Streptolysin O (SLO)*#           Bensi et al 2012
50 
Serine esterase (Sse)           Liu et al 2007
89 
Arginine deiminase (ADI)#           Henningham et al 2012
14 
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Footnotes: 
^All query sequences were based on the M1 GAS strain MGAS5005 as a query reference sequence (if present). Otherwise, query sequences 
from original published reference were used.  
*Components of the Novartis (GSK) combination vaccine (Bensi et al 2012)50 
+Components of the Spy7 combination vaccine (Reglinski et al., 2016)94 
#Components of the Combo#5 vaccine (Rivera-Hernandez et al., 2016)95 
 
Rib-like cell wall protein (R28)           
Stalhammar-Carlemalm et 
al 199990 
Streptococcal hemoprotein receptor (Shr)      Huang et al 2011
91 
Streptococcal immunoglobulin-binding protein 35 (Sib35)      Okamoto et al 2005
92 
Streptococcal protective antigen (Spa)      Dale et al 1999
93 
Oligopeptide-binding protein (OppA)+      Reglinski et al 2016
94 
Putative pullulanase (PulA)+      Reglinski et al 2016
94 
Nucleoside-binding protein (Spy0942)+      Reglinski et al 2016
94 
Hypothetical membrane associated protein (Spy0762) +      Reglinski et al 2016
94 
Cell surface protein (Spy0651) +           Reglinski et al 2016
94 
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Supplementary Table 2. GAS strains used in this study. 
 
See separate Excel file  
 
Supplementary Table 3. List of 890 core GAS genes identified as having recombinogenic signatures as defined by fastGEAR17. 
 
See separate Excel file  
 
Supplementary Table 4. List of 416 "non-recombinogenic" core GAS genes with MGAS5005 reference genome annotations.  
 
See separate Excel file  
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Supplementary Table 5: Strain and genome characteristics of 30 new globally sampled GAS reference genomes.  
Strain ID Country of 
isolation 
Site emm-
subtype 
Other 
emm-
subtype 
M-
cluster 
MLST genome 
size (bp) 
CDS 
(no.) 
plasmid 
size (bp) 
Prophage 
(no.) 
GenBank 
Accession 
GAS13475 New Zealand Throat 197.0 - AC2 998 1797172 1800  3 Pending 
NS178 Australia Skin 54.1 166.2 D1 302 1742565 1708  1 Pending 
20123V1I1 Fiji Blood 100.0 167.0 D2 119 1839531 1864  3 Pending 
31010V3S1 Fiji Skin 123.0 205.0 D3 325 1768816 1708  10 Pending 
NS5694 Australia Skin 230.0 - D4 205 1826832 1813  4 Pending 
31165V2S1 Fiji Skin 93.4 174.1, 
156.0 
D4 814 1701466 1642  10 Pending 
NS5958 Australia Skin 56.0 205.0 D4 115 1825427 1833  3 Pending 
31041V2S1 Fiji Skin 70.0 174.1 D4 10 1826467 1818  3 Pending 
K23890 Kenya Soft 
Tissue 
97.1 - D5 283 1812090 1774  1 Pending 
Bra006 Brazil Throat 68.2 - E2 989 1747924 1691  1 Pending 
30109V1T1 Fiji Throat 92.0 - E2 1026 1758778 1718 3453 1 Pending 
14GA0958 New Zealand Blood 90.5 - E2 184 1764969 1703  8 Pending 
NS365 Australia Blood 58.0 236.1 E3 176 1888806 1902  4 Pending 
31132V1S1 Fiji Skin 25.0 159.0 E3 1032 1835714 1832  2 Pending 
A1268 India Blood 1.0 - E3 28 1834762 1841  3 Pending 
NS7124 Australia Throat 124.0 - E4 199 1790668 1759  1 Pending 
NS5128 Australia Throat 77.0 149.2 E4 588 1806314 1782  1 Pending 
A995 India Skin 22.8 - E4 360 1950616 1960 3626 4 Pending 
GAS02198 New Zealand Throat 78.3 - E1 1000 1806521 1767  1 Pending 
31143V3S1 Fiji Skin 89.14 236.2 E4 380 1806344 1797 3043 2 Pending 
Bra010 Brazil Throat 64.3 205.1 E5 1008 1779766 1769  2 Pending 
NS20 Australia Skin 75.1 170.0 E6 607 1887700 1870  2 Pending 
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K3534 Kenya Blood 65.0 - E6 716 1789855 1734  1 Pending 
GAS11291 New Zealand Throat 11.0 202.1 E6 547 1809631 1793  2 Pending 
31034V1S1 Fiji Skin 105.0 - M105 954 1800116 1757 2645 1 Pending 
NS4972 Australia Skin 55.0 - M55 100 1899479 1908  4 Pending 
NS7259 Australia Throat NA 138.0 NA 612 1788166 1788  3 Pending 
K17300 Kenya Soft 
Tissue 
stg866.1 166.1 NT 450 1816007 1786  1 Pending 
14GA0287 New Zealand Throat 74.0 156.0 M74 120 1861037 1873  5 Pending 
31034V4S1 Fiji Skin 57.0 166.1 M57 1025 1756622 1718 6485 1 Pending 
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Supplementary Table 6: Frequency, size (length) and relative rates of recombination within 
36 PopPUNK phylogroups. 
 
See separate Excel file  
 
Supplementary Table 7: Top 5 k-mers associated with invasiveness as determined by 
pyseer73. 
Gene/Locus Tag Product k-mer Coordinates Log10(p-value) 
M5005_Spy1733 Hypothetical protein 1696410..1696509  7.987 
Intergenic  1810451..1810550   7.410 
M5005_Spy1061 LacI family transcriptional 
regulator 
1032656..1032755  7.261 
M5005_Spy0554 
(ezrA) 
Cell division regulation 545543..545642  7.257 
M5005_Spy1723 
(isp) 
immunogenic secreted protein 1687402..1687501  7.146 
 
Supplementary Table 8: Position of amino acid variants within the Streptolysin O protein 
(SLO) and the consensus sequence of the SLO mature protein (as plotted in Fig 3a and 3c). 
 
See separate Excel file  
 
Supplementary Table 9: Position of amino acid variants within the C5a peptidase (ScpA) 
protein and the consensus sequence of the ScpA mature protein (as plotted in Fig 3a and 3d). 
 
See separate Excel file  
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Supplementary Table 10: Mutation sensitivity analysis of amino acid variants within the 
mature Streptolysin O protein. 
 
 
 
 
 
 
Footnotes: 
aa (amino acid) . 
& Diversity hotspot as determined by a minor amino acid frequency of >10% in the mature 
enzymatic protein (amino acids 103-501). Relative location is plotted in Figure 3c. 
$ Number in brackets refers to the total number of 2,083 GAS genomes carrying the 
respective amino acid. 
# Determined using the SuSPect37 platform (ranked between 1-9; 1 representing “very low” 
and 9 as “very high” mutational sensitivity). Sensitivity being a measure of likely functional 
consequence of the observed amino acid mutation. 
 
 
 Amino acid position within Streptolysin O protein   
hotspot& HS1 HS2 HS3 HS4 HS5 
aa position 172 182 324 450 470 
major aa$ R(1242) N(1305) E(1204) T(1843) Q(1260) 
minor aa$ M(841) D(778) D(879) S(240) R(823) 
mutational 
sensitivity 
(minor aa) # 
M=6 D=2 D=1 S=2 R=2 
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Supplementary Table 11: Mutation sensitivity analysis of amino acid variants within the mature C5a peptidase protein. 
Amino acid position within C5a peptidase protein 
hotspot HS1 HS2 HS3 HS4 HS5 HS6 HS7 HS8 HS9 HS10 HS11 HS12 
aa position 110 146 247 346 348 350 376 448 450 451 605 637 
major aa$ Q(1745) T(1634) R(1921) A(1367) Q(1229) D(1711) M(1553) D(1534) P(1351) Q(1381) K(1709) H(1948) 
minor aa$ H(338) A(360) I(150) D(622) H(420) A(346) T(530) E(549) S(617) K(692) T(374) L(131) 
 
 
S(89) K(12) E(93) K(434) G(19) 
  
L(98) P(10) 
 
Y(4) 
 
   
V(1) 
 
N(7) 
  
R(11) 
   
 
        
F(6) 
   
mutational 
sensitivity 
(minor aa) # 
H=2 A=2 
S=2 
I=1 
K=3 
D=3 
D=2 
V=2 
H=2 
K=2 
A=2 
G=3 
N=3 
T=3 E=1 S=5 
L=5 
R=6 
F=6 
K=2 
P=3 
T=1 L=1 
Y=2 
 
Amino acid position continued 
hotspot& HS13 HS14 HS15 HS16 HS17 HS18 HS19 HS20 
aa position 665 669 671 679 697 942 959 999 
major aa$ V(1878) A(1963) R(1804) Q(1952) T(1111) T(1671) V(1775) A(1679) 
minor aa$ I(200) V(120) Q(279) P(131) K(972) A(412) I(308) G(404) 
  A(5)               
mutational 
sensitivity 
(minor aa) # 
I=1 
A=3 
V=2 Q=1 P=1 K=2 A=2 I=1 G=1 
Footnotes: 
aa (amino acid) 
& Diversity hotspot as determined by a minor amino acid frequency of >10% in the mature enzymatic protein (amino acids 97-1032). Relative 
location is plotted in Figure 3d 
$ Number in brackets refers to the total number of 2,083 genomes carrying the respective amino acid 
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# Determined using the SuSPect37 platform (ranked between 1-9; 1 representing “very low” and 9 as “very high” mutational sensitivity). Sensitivity 
being a measure of likely functional consequence of the observed amino acid mutation.  
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Supplementary Table 12: Theoretical global coverage of combination vaccines based on the genome database presented in this study.  
  Theoretical Vaccine Coverage 
Vaccine  Vaccine antigens Europe Oceania North 
America 
South 
America 
Asia East Africa TOTAL 
    (n = 242) (n = 906) (n = 474) (n = 51) (n = 79) (n = 328) (n = 2080) 
3-component  SLO+ 98% >99% >99% >99% 97% 98% >99% 
 (GSK)50 SpyCEP+ 99% >99% 99% >99% 99% >99% >99% 
  SpyAD+ >99% >99% >99% >99% >99% >99% >99% 
  any antigen >99% >99% >99% >99% >99% >99% >99% 
Spy794 Spy0651+ >99% >99% >99% >99% >99% >99% >99% 
  Spy0762+ >99% >99% >99% >99% >99% >99% >99% 
  Spy0942+ >99% >99% >99% >99% >99% >99% >99% 
  PulA+ >99% >99% >99% >99% 99% 99% >99% 
  OppA+ >99% >99% 99% >99% 99% 99% >99% 
  SpyAD+ >99% >99% 99% >99% 99% 99% >99% 
  ScpA+ 90% >99% 96% >99% 99% 99% 98% 
  any antigen >99% >99% >99% >99% >99% >99% >99% 
Combo #595 TF+ >99% >99% >99% 98% >99% >99% >99% 
  ScpA+ 90% >99% 96% >99% 99% 99% 98% 
  SpyCEP+ 99% >99% 99% >99% 99% >99% >99% 
  ADI+ >99% >99% 99% >99% 99% 99% >99% 
  SLO+ 98% >99% >99% >99% 97% 98% >99% 
  any antigen >99% >99% >99% >99% >99% >99% >99% 
StreptInCor 32 B cell epitope@ 39% 25% 15% 12% 34% 14% 22% 
  T cell epitope@ 8% 17% 3% 2% 4% 9% 11% 
  common epitope@ 35% 16% 14% 10% 30% 11% 18% 
  any epitope 39% 26% 15% 12% 34% 17% 23% 
S2 - J8.033 S2@ >99% >99% >99% >99% >99% >99% >99% 
  J8$ 45% 41% 31% 31% 57% 25% 37% 
  any epitope >99% >99% >99% >99% >99% >99% >99% 
30-valent 30 30 emm families& 71% 33% 75% 53% 73% 28% 48% 
30-valent  30 emm families& 71% 33% 75% 53% 73% 28% 48% 
with Mrp40 MrpI@ 8% 9% 12% 4% 5% 4% 8% 
  MrpII@ 6% 13% 6% 18% 6% 3% 9% 
  MrpIII@ 5% 4% 7% 4% 9% 6% 5% 
  any antigen 77% 51% 83% 59% 83% 33% 60% 
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Footnotes: 
+ Defined by BlastN as 70% homology over 70% length of the nucleotide sequence. 
@ Peptide sequence carriage is defined by BlastP at 95% homology over 95% of query length. 
$ Defined as clustering at 90% of the J8 allelic database (encompasses J8.0, J8.57 or J8.59) by CD-HIT EST. 
& Defined at the emm family level (irrespective of emm sub-type). 
 
